Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
A company spokesperson told Reuters that Hims has not compromised on safety or efficacy and uses a liposomebased technology intended to support absorption
Retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, making it distinct from approved agents such as semaglutide (Wegovy) and tirzepatide (Mounjaro)
Long-term success depends on education, lifestyle changes, and medical guidance
8mg reached -22.1% and 4mg reached -17.1%
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
US$ 20.89
US$ 24.95
US$ 28.14
US$ 21.24
